Bicycle Therapeutics plc

31.60+0.4100+1.31%Vol 66.43K1Y Perf 94.80%
Jul 30th, 2021 16:00 DELAYED
BID31.40 ASK31.61
Open31.20 Previous Close31.19
Pre-Market- After-Market-
 - -  - -%
Target Price
45.00 
Analyst Rating
Strong Buy 1.00
Potential %
42.41 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     52.56
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap760.86M 
Earnings Rating
Sell
Price Range Ratio 52W %
75.21 
Earnings Date
4th Aug 2021

Today's Price Range

30.1532.25

52W Range

15.2536.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-10.51%
1 Month
4.08%
3 Months
1.94%
6 Months
17.87%
1 Year
94.80%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCYC31.600.41001.31
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.66-0.73-10.61
Q04 2020-0.50-0.83-66.00
Q03 2020-0.66-0.5221.21
Q02 2020-0.55-0.67-21.82
Q01 2020-0.02-0.63-3 050.00
Q04 2019-0.54-0.2553.70
Q03 2019-0.55-0.533.64
Q02 2019-0.53-1.40-164.15
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.72-1.41Negative
9/2021 QR-0.6411.11Positive
12/2021 FY-2.796.69Positive
12/2022 FY-3.295.73Positive
Next Report Date4th Aug 2021
Estimated EPS Next Report-0.72
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume66.43K
Shares Outstanding24.08M
Trades Count1.10K
Dollar Volume4.50M
Avg. Volume142.88K
Avg. Weekly Volume92.74K
Avg. Monthly Volume212.26K
Avg. Quarterly Volume108.61K

Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 31.6 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 66.43K shares and market capitalization of 760.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.

The one-year performance of Bicycle Therapeutics plc stock is 94.8%, while year-to-date (YTD) performance is 76.04%. BCYC stock has a five-year performance of %. Its 52-week range is between 15.25 and 36.99, which gives BCYC stock a 52-week price range ratio of 75.21%

Bicycle Therapeutics plc currently has a PE ratio of -12.50, a price-to-book (PB) ratio of 5.85, a price-to-sale (PS) ratio of 87.36, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.93%, a ROC of -42.80% and a ROE of -48.78%. The company’s profit margin is -%, its EBITDA margin is -492.90%, and its revenue ttm is $9.50 Million , which makes it $0.39 revenue per share.

Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1), with a target price of $45, which is +42.41% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.00, ATR14 : 2.01, CCI20 : -86.17, Chaikin Money Flow : 0.03, MACD : 0.51, Money Flow Index : 87.59, ROC : -6.56, RSI : 43.72, STOCH (14,3) : 21.20, STOCH RSI : 0.09, UO : 44.26, Williams %R : -78.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Kate Bingham (Sold 44 895 shares of value $1 526 466 ), Kevin Lee (Option Excercise at a value of $2 308 348), Kevin Lee (Sold 194 882 shares of value $6 217 756 ), Nicholas Keen (Sold 30 000 shares of value $934 843 ), Nigel Crockett (Option Excercise at a value of $945 474), Nigel Crockett (Sold 80 000 shares of value $2 592 140 ), Pierre Legault (Option Excercise at a value of $394 837), Pierre Legault (Sold 45 000 shares of value $1 382 621 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.

CEO: Kevin Lee

Telephone: +44 1223261503

Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB

Number of employees: 81

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

57%43%

Bearish Bullish

65%35%

News

Stocktwits